BERRY GENOMICS(000710) 证券之星·2025-05-21 13:36Summary of Key Points Core Viewpoint - The announcement details a significant change in shareholding for Chengdu Berry Genomics Technology Co., Ltd. (referred to as "the Company") due to forced execution of shares by the controlling shareholder Gao Yang and his associate Hou Ying, resulting in a reduction of their holdings without affecting the company's control or operational stability [1][2]. Shareholding Changes - Gao Yang's shares decreased by 5,580,549 shares, representing a 1.58% reduction in total shareholding [1]. - Hou Ying's shares decreased by 1,135,661 shares, accounting for 0.32% of total shareholding [1]. - The total reduction in shareholding for both Gao Yang and Hou Ying amounts to 6,716,210 shares, which is 1.90% of the total share capital [1]. Execution Details - The forced execution of shares occurred due to a stock pledge default, with the shares being sold through centralized bidding by Guoxin Securities from August 1, 2024, to October 31, 2024, and again on May 20, 2025 [1]. - The execution process did not lead to a change in the company's control, nor did it have a significant adverse impact on the company's production, financial status, or governance structure [2].